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BACKGROUND AND OBJECTIVES Zinc plays a role in skin health, and preliminary data have shown its
beneficial effects for melasma. We compared the effect of topical zinc with that of hydroquinone as the
standard treatment on severity of melasma.
PATIENTS AND METHODS Ninety-three women with melasma were randomized to receive zinc sulfate 10%
or hydroquinone 4% solutions once daily for 2 months. They were followed for an additional 3 months while
using sunscreen. The severity of melasma was assessed at baseline and at 2 and 5 months using the Melasma
Area and Severity Index (MASI).
RESULTS Eighty-two patients completed the study. The MASI score fell significantly in both groups, but a
greater decrease was seen in those who received hydroquinone (43.5  15.5% vs 18.6  20.8%, p < .001).
Postinflammatory pigmentation occurred in 5.2% of the zinc group and irritation in 30.9% of the hydroquinone
group.
CONCLUSION Topical zinc therapy is not highly effective in reducing the severity ofmelasma, but further trials
are needed to determine whether adding zinc to current topical treatments could improve treatment response.
The authors have indicated no significant interest with commercial supporters.
Melasma is one of the most common anddisturbing cosmetic disorders with skin
darkening. Pigmentation is brown to gray and
usually affects the cheeks, forehead, nose, and upper
lip. Melasma is more common in women; other
known risk factors are pregnancy, sun exposure, and
some medications such as hormones and anti-
epileptic medication.1 It is more common in Asian
population than in other races.2 In Iran, there have
not been enough population based studies to deter-
mine the prevalence of melasma, although Moin and
colleagues reported a prevalence of 15.8% for
melasma in pregnant women.3
Current treatments have not been successful at
completely correcting the skin pigmentation of
melasma.4 Suggested medications include sunscreen,
bleaching creams (e.g., hydroquinone (HQ)), acne
creams (e.g., azelaic acid), and topical retinoids
alone or in combination.4,5 Other suggested treat-
ment strategies are lasers, intense pulse light, and
chemical peels. According to a review of randomized
trials by Rajaratnam and colleagues, tretinoin and
triple-combination creams are the most-effective
treatments for melasma.4 Taylor and colleagues
reported a maximum efficacy of 26.1% for complete
resolution,6 but combination therapies are associ-
ated with more side effects (erythema, desquama-
tion, burning, dryness, and pruritus), which are
most common in patients receiving tretinoin
and hydroquinone (80%), followed by tretinoin and
fluocinolone acetonide.6
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As a physical blocker, zinc can provide broader
protection against the sun than chemical blockers.7
To the best of our knowledge, only a self-con-
trolled study has been performed regarding the
beneficial effects of topical zinc in melasma.
That study reported that topical zinc sulfate (ZS)
10% plus sunscreen significantly reduced the
severity of melasma.8 According to the evidence,
zinc has an important role in skin health,
and topical zinc has various beneficial effects in
the treatment of skin disorders,7,9 but there are
not enough data establishing that zinc could be
effective in the treatment of melasma. The aim
of our study was to investigate whether ZS is
effective in reducing the severity of melasma
by comparing it with HQ, a standard treatment
for melasma.
Materials and Methods
Patients and settings
This randomized, double-blind, controlled trial
was conducted on women with melasma referred
to the outpatient dermatology clinic of Dr. Shariati
Hospital, Isfahan (Iran) during 2010. We included
all patients with any type of melasma (dermal,
epidermal, or mixed) who had taken no medica-
tion within the 3 months before the study. Exclu-
sion criteria were pregnancy, breast feeding, and
using other medications, including hormones and
antiepileptic agents. With a (type I error) = 0.05,
study power = 0.8, and a minimum expected
difference of 1 in melasma severity score, sample
size was calculated as 39 patients in each group.
The ethics committee of Islamic Azad University
(Najaf Abad Branch) approved the study, and all
patients signed informed consent before entering
the clinical trial.
Intervention
Using a list generated using Random Allocation
Software,10 patientswere randomly assigned to oneof
two groups of ZS 10% or HQ 4%. The ZS 10%
solution containedZS crystals dissolved in90%water
and 10% propylene glycol. The HQ solution con-
tained 4%hydroquinone in 70%alcohol, 20%water,
and 10% propylene glycol. Patients started using the
solution for 2 hours once daily at night, gradually
increasing its use to the complete night after 1 week.
After washing the face in the morning, subjects
covered their face with sunscreen (MY, SPF 60; Act
Cosmetics Co., Tehran, Iran) and reapplied every
4 hours. This treatment with the solutions continued
for 2 months, and patients were advised to use
sunscreen for 3 months after the end of the treatment
as well. Solutions were in the same boxes labeled A
and B, and treatment status was not disclosed to
investigators or patients throughout the study.
Assessments
We used transparent graph paper to precisely
measure the affected area. A Wood lamp was used to
distinguish epidermal, dermal, and mixed lesions.
Patients were seen every 2 weeks, and melasma
severity, using the Melasma Area and Severity Index
(MASI), and drug reactions were evaluated. To
calculate the MASI score, the sum of the severity
grade for darkness (D) and homogeneity (H) was
multiplied by the numerical value of the areas (A)
involved and by the percentages of the four facial
areas. Total MASI score: (forehead 0.3
[D+H] 9 A) + (right malar 0.3 [D+H] 9 A) + (left
malar 0.3 [D+H] 9 A) + (chin 0.1 [D+H] 9 A).11
Patients were seen 3 months after the treatment
finished, and the severity of their melasma was
measured again.
Statistical analyses
Data were analyzed using SPSS for Windows version
16.0 (SPSS, Inc., Chicago, IL). Independent-sample
t-tests and Mann–Whitney tests were used to com-
pare parametric and nonparametric quantitative
variables between groups respectively. Chi-square or
Fisher exact tests were used to compare qualitative
variables. Repeated-measure analysis was performed
to evaluate trends in changes in MASI score during
the study. Univariate and multivariate (linear
regression analysis) analyses were conducted to find
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factors associated with treatment responses. p < .05
was set as the level of significance in all analyses.
Results
Demographic data and disease characteristics
Ninety-three patients were included into the trial.
Eleven dropped out within 4 weeks after starting the
study (n = 9 ZS, n = 2 HQ). Reasons for dropping
out included drug side effects; distance from the
treatment center and unwillingness to be followed.
Data from 82 patients were used for the analyses.
Patient data and disease characteristics are presented
in Table 1. There were no significant differences
between the two groups in demographic or disease
characteristics.
Changes in MASI scores
MASI scores at baseline and at 2 and 5 months are
presented in Table 2. Because two patients in the ZS
group dropped out after the second month because
of drug side effects, data from 38 patients were
included in repeated-measure analysis from this
TABLE 1. Participant and Disease Characteristics
Characteristic Zinc Sulfate, n = 40 Hydroquinone, n = 42 p-Value
Age, mean  SD 33.1  9.1 35.2  8.1 .27*
Type, n (%) .43†
Epidermal 24 (60) 27 (64.2)
Mixed 16 (40) 15 (35.7)
Pattern, n (%) .51†
Centrofacial 28 (70) 26 (61.9)
Malar 10 (25) 15 (35.7)
Mandibular 2 (5) 1 (2.3)
Family history, n (%) 29 (72.5) 25 (59.5) .16†
Onset at pregnancy, n (%) 25 (62.5) 21 (50) .18†
Duration, months, mean  SD 6.4  5.1 6.0  4.8 .73*
Sun exposure, h/d, mean  SD 1.31  0.57 1.10  0.54 .09*
Baseline Melasma Area and Severity
Index score, mean  SD
6.2  2.2 6.4  1.6 .63*
SD, standard deviation.
*Independent sample t-test or Mann–Whitney test.
†Chi-square or Fisher exact test.
TABLE 2. Melasma Area and Severity Index Scores
During the Trial According to Group
Zinc Sulfate,
n = 38
Hydroquinone,
n = 42
p-Value*
Mean  Standard
Deviation
Baseline 6.3  2.1 6.4  1.6 .93
Month 2 5.0  1.9 3.6  1.3 <.001
Month 5 5.1  2.0 3.9  1.4 .002
p-value† <.001 <.001
p-value‡ .02
*Independent-sample t-test or Mann–Whitney test.
†Within- and ‡between-group repeated-measure test.
Figure 1. Changes in Melasma Area and Severity Index
scores from baseline to month 5.
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group. Analyses showed that MASI score fell
significantly after the second (15.9  29.5%) and
fifth (18.6  20.8%) months in the ZS group and in
the HQ group (43.5  15.5% and 38.3  18.9%,
respectively (within-group analysis, p < .001).
MASI score fell more in the HQ than the ZS group
(between-group analysis, p = .02; Figure 1).
Predictors of response
In univariate analyses, the response to treatment was
better in patients with epidermal (32.8%) than
mixed (22.5%) melasma (p = .04). Subgroup anal-
ysis showed that this difference occurred only in
patients taking HQ (44.8% vs 26.5%, p = .002) and
not in those taking ZS (18.8% vs 18.4%, p = .95).
Regular use of sunscreen was associated with a
greater decrease in MASI score (r = 0.331,
p = .003). Other variables were not associated with
response to treatment in univariate analyses. Linear
regression analysis using a stepwise model control-
ling for all possible predictors showed that taking
HQ (b = 0.459, p < .001) and regular use of
sunscreen (b = 0.315, p = .001) were associated
with a greater decrease in MASI score. Age, type of
melasma, family history, sun exposure, melasma at
pregnancy, and pattern of melasma were not sig-
nificantly associated with a change in MASI score.
Drug side effects
Mild postinflammatory pigmentation occurred in
two patients in the ZS group after the second month
of therapy, but it resolved completely after treatment
with topical tretinoin. The frequency of irritation
was significantly higher in the HQ (30.9%)than the
ZS (2.5%) group (p < .001). Recurrence rate was
not different between the two groups (17.5% vs
23.8%, p = .33).
Discussion
Melasma is a skin hyperpigmentation disorder that
does not resolve completely in most patients with
current medications.4,12 For the first controlled
comparative trial, we considered zinc as a possible
treatment for melasma because of its role in skin
health. Zinc has antioxidative and anti-inflamma-
tory properties, which may act as a regenerative
substance in damaged skin. It can also protect skin
from ultraviolet radiation, especially irritated skin,
and so may prevent extra activity of melano-
cytes.13,14 These mechanisms make zinc a potential
therapeutic option for the treatment of melasma.
Our data showed that topical zinc therapy is not
highly effective for melasma. Although it reduced
the MASI score after 2 months of treatment, and
this effect was stable for at least 3 months after
therapy, the MASI score fell more in the HQ group.
These results show that ZS is not a suitable single
treatment for melasma, and that it may be better to
combine it with other topical agents such as HQ.
To the best of our knowledge, there is only one
previous report regarding the therapeutic effects of
zinc on melasma. In the study by Sharquie and
colleagues, treatment with topical ZS 10% for
2 months resulted in 49.8% improvement in MASI
score (from 9.45 to 4.70).9 This greater percentage
improvement in MASI score compared with our data
may be as a result of several factors. Although the
treatment plan was not clear in Sharquie study, zinc
was applied twice daily in the previous reportwhereas
we administered it once daily at night and thus did not
take advantage of the sun-protective effects of zinc.
Baseline severity of melasma was worse in the
Sharquie and colleagues study than in ours (baseline
MASI = 6.3), whereas in both studies, the finalMASI
score fell to approximately the same level. The
previous study was an uncontrolled trial including 28
patients, half ofwhomdidnot complete the study, and
it might be the case that mostly patients with a better
response continued the follow-up. Regardless, both
studies showed the beneficial effects of zinc in the
treatment of melasma. Also, adjusting for confound-
ing factors,multivariate analysis inour study supports
that long-term use of sunscreen is important in the
treatment of melasma.15
With regard to side effects, irritation occurred less
commonly with ZS than HQ. Although, ZS caused
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postinflammatory pigmentation in two cases in our
study, this side effect was mild and resolved com-
pletelywith topical tretinoin. Sharquie and colleagues
did not report considerable side effects with topical
zinc.9 These results indicate that topical use of zinc is
safe for long-term treatment of melasma, however, it
is not known whether side effects are greater with
combination therapies. Further trials are needed to
evaluate the therapeutic effects and safety of zinc in
combination with other agents for the treatment of
melasma. Considering the role of zinc deficiency in
skin health, oral zinc could be added to other topical
therapies. This needs to be investigated.
There are some limitations to this study. We did not
consider a sunscreen-only arm to evaluate the
additional benefits of zinc over sunscreen. Also,
considering the high recurrence rate of melasma,
long-term follow-up was required to evaluate the
effectiveness of topical zinc.
Conclusions
This study showed that topical zinc therapy has little
beneficial effect in reducing the severity of melasma,
and as a single agent, its effectiveness is much less
than that of hydroquinone. It is possible that adding
zinc to current topical treatments of melasma could
increase the treatment response, which needs further
trials regarding safety and efficacy.
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